CA Patent

CA2537665C — Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Assigned to Andrx Laboratories LLC · Expires 2012-08-14 · 14y expired

What this patent protects

A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.

USPTO Abstract

A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.

Drugs covered by this patent

metformin-hydrochloride (METFORMIN HYDROCHLORIDE)

Patent Metadata

Patent number: CA2537665C
Jurisdiction: CA
Classification: —
Expires: 2012-08-14
Drug substance claim: No
Drug product claim: No
Assignee: Andrx Laboratories LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.